Single-domain antibody fusion protein and application thereof

Abstract

The invention provides a single-domain antibody fusion protein. The single-domain antibody fusion protein comprises one or more single-domain antibodies fused with cytokines, in particular one or moreanti-PD-1 single-domain antibodies fused with IL-12 or IL-2. The invention also provides an application of the single-domain antibody fusion protein in preparing medicines for treating tumors. The fusion protein provided by the invention actively combines the advantages of small molecules, good permeability, high stability and the like of single-domain antibodies with the immunoregulation and thelike of the cytokines, and has a better anti-tumor effect.

Description

technical field [0001] The present invention relates to a fusion protein, especially a fusion protein comprising an anti-PD-1 single domain antibody and a cytokine. Background technique [0002] In mammalian cells, the immune system is regulated by immune checkpoints. Two classes of immune regulators are involved in this pathway, including co-stimulatory and co-inhibitory signaling molecules (1). In healthy human cells, the immune system's T-cell activity is suppressed due to tight regulation by immune checkpoint inhibitors, thereby avoiding the devastating effects of autoimmunity and an overactive inflammatory response. However, cancerous cells also use this inhibitory pathway to avoid immune recognition and destruction. To be able to harness the immune system to destroy cancer cells, this immunosuppressive effect needs to be eliminated, thereby removing the inhibition of immune checkpoints (2,3). Currently, monoclonal antibodies that specifically bind inhibitory factors...

AI Technical Summary

Problems solved by technology

Even so, existing therapeutic antibodies still have problems such as excessive molecular weight, poor stability, and limited therapeutic effect

Images